Categories: News

The National Pancreas Foundation Launches First Real-Time Patient Registry Powered by SeqsterOS

NPF launches the nation’s largest pancreatic disease patient registry at the Digestive Disease Week 2022 Conference

SAN DIEGO–(BUSINESS WIRE)–The National Pancreas Foundation (“NPF”), a nonprofit organization that provides hope for those suffering from pancreatitis and pancreatic cancer, announced today at Digestive Disease Week 2022 in San Diego, the launch of the country’s largest, most inclusive pancreatic disease patient registry powered by SeqsterOS. The patient-centric registry gives patients and their caregivers the ability to create their longitudinal patient records with real-time data from any EHR, genomic DNA test, and wearable/remote monitoring device.


“We are so thrilled to provide the exciting capabilities of SeqsterOS for Patient Registries and Clinical Studies to our patients as well as to researchers who wish to better understand pancreatic disease and develop therapies faster,” said Chief Executive Officer at NPF, David Bakelman. “Now, we can enable greater collaboration amongst researchers and our foundation, improve the quality of patient care, and significantly impact outcomes for patients with pancreatic disease.”

Visit NPF.SEQSTER.COM to register today.

Until now registries did not have access to longitudinal patient data that is true Real World Data. With the SeqsterOS, the patients are engaged in the study and are able to see all of their health history in one private and secure location, while researchers can benefit from consented de-identified data that streams in real-time. NPF is executing on its mission to improve the quality of patient care, and significantly impact outcomes for patients with pancreatic disease by giving each patient the ability to connect, own and share their data.

The registry will put real-world patient data in the hands of cutting-edge researchers who are working tirelessly to improve care and develop new and improved therapies for individuals suffering from pancreatic disease.

“There is no better conference than DDW for NPF to announce their patient registry powered by SeqsterOS,” exclaimed Ardy Arianpour, CEO & Co-Founder of Seqster. “The NPF registry with SeqsterOS tackles traditional hurdles faced by patient registries from two angles: nationwide interoperability and patient engagement. Without these two elements, a patient-matched longitudinal health record that streams in to enable effective research is not possible. We are excited that NPF had the vision to select SeqsterOS to empower their patients, caregivers, and researchers and accelerate pancreatic disease research while better managing their health.”

About Seqster

Seqster is the leading healthcare technology company that breaks down health data silos at scale. Its enterprise operating system aggregates disparate health data sources into a single, 360-degree view of a patient in real-time, solving a multitude of challenges for life sciences, patient engagement and data interoperability.

Seqster has nationwide coverage of EHRs from hospitals and medical groups, genomic DNA, wearables, pharmacy and social determinants of health data. Through its customizable white-label approach, Seqster provides accelerated access to de-identified, tokenized, real-time data and comprehensive curated data to address critical needs across the healthcare continuum.

Seqster is privately held and headquartered in San Diego. To learn more about the Seqster Operating System for Patient Registries and Clinical Studies, please contact us at info@seqster.com or visit www.seqster.com.

About The National Pancreas Foundation

The National Pancreas Foundation (NPF) is a nonprofit organization that provides hope for those suffering from pancreatitis and pancreatic cancer through funding cutting edge research, advocating for improved therapies, and providing continuous support and education for patients, caregivers, and health care professionals.

The National Pancreas Foundation (NPF) was founded in 1997. Since that time NPF has made it our mission to significantly influence the physician and pancreatic research community and provide much needed education and resources to patients and their families who are afflicted by pancreatic disease. NPF advocates for increased research funding for diseases of the pancreas from both the public and private sectors. NPF works with government, for-profit and non-profit organizations as well as the biopharmaceutical industry to improve the level of awareness, interest and investment in research for pancreas disease.

To learn more, visit: https://pancreasfoundation.org/
Or Register at www.npf.seqster.com

Contacts

Seqster Media Contact:
Bill Douglass

Gotham Communications for Seqster

+1 (646) 504-0890

press@seqster.com

The National Pancreas Foundation (NPF) Media Contact:
Elizabeth Johnston

Launch My Media

+1 (954) 540-2069

Registry@pancreasfoundation.org

Staff

Recent Posts

Izotropic Corporation Announces Closing of First Tranche of Non-Brokered Private Placement

Vancouver, British Columbia--(Newsfile Corp. - June 14, 2024) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE:…

2 hours ago

Akanda Corporation Announces Completion of F-3 Shelf Registration Statement

London, United Kingdom--(Newsfile Corp. - June 14, 2024) - Akanda Corp. (NASDAQ: AKAN) ("Akanda" or…

2 hours ago

Glaukos Announces Agreements to Exchange $230 Million in Principal Amount of Its 2.75% Convertible Senior Notes Due 2027 for Common Stock

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company, today…

3 hours ago

Justera Health Signs LOI to Acquire Popular Cannabis Brand Port North

Toronto, Ontario--(Newsfile Corp. - June 14, 2024) - Justera Health Ltd. (CSE: VTAL) (OTC Pink:…

3 hours ago

OneMedNet Partners with Leading Clinical Trial Design and Software Company in Significant Data License Agreement

Partner’s software products and services are utilized by hundreds of life science organizations, including the…

3 hours ago

Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis

MRT-6160, a VAV1-directed molecular glue degrader (MGD), inhibits disease progression, pro-inflammatory cytokines and autoantibody production…

3 hours ago